Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 2
2008 3
2009 13
2010 16
2011 14
2012 13
2013 9
2014 5
2015 10
2016 6
2017 5
2018 9
2019 9
2020 7
2021 7
2022 4
2023 3
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

123 results

Results by year

Filters applied: . Clear all
Page 1
Besifloxacin.
[No authors listed] [No authors listed] 2018 Dec 3. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2018 Dec 3. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999822 Free Books & Documents. Review.
Maternal use of besifloxacin eye drops presents negligible risk for the nursing infant. To substantially diminish the amount of drug that reaches the breastmilk after using eye drops, place pressure over the tear duct by the corner of the eye for 1 minute or more, then rem …
Maternal use of besifloxacin eye drops presents negligible risk for the nursing infant. To substantially diminish the amount of drug …
The role of besifloxacin in the treatment of bacterial conjunctivitis.
Mahvan TD, Hornecker JR, Buckley WA, Clark S. Mahvan TD, et al. Ann Pharmacother. 2014 May;48(5):616-25. doi: 10.1177/1060028014524175. Epub 2014 Feb 24. Ann Pharmacother. 2014. PMID: 24566460 Review.
OBJECTIVE: To evaluate the role of besifloxacin in bacterial conjunctivitis treatment. DATA SOURCES: Searches were made on MEDLINE/PubMed and EMBASE (January 2007 to January 2014) using the terms besifloxacin and Besivance. ...Besifloxacin was compared with p …
OBJECTIVE: To evaluate the role of besifloxacin in bacterial conjunctivitis treatment. DATA SOURCES: Searches were made on MEDLINE/Pu …
Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis.
Chang MH, Fung HB. Chang MH, et al. Clin Ther. 2010 Mar;32(3):454-71. doi: 10.1016/j.clinthera.2010.03.013. Clin Ther. 2010. PMID: 20399984 Review.
OBJECTIVE: This article provides an overview of the pharmacology, clinical efficacy, and tolerability of ophthalmic besifloxacin when used for the treatment of bacterial conjunctivitis. METHODS: Relevant reports pertaining to the pharmacology, efficacy, and tolerability of …
OBJECTIVE: This article provides an overview of the pharmacology, clinical efficacy, and tolerability of ophthalmic besifloxacin when …
Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections.
Mah FS, Sanfilippo CM. Mah FS, et al. Ophthalmol Ther. 2016 Jun;5(1):1-20. doi: 10.1007/s40123-016-0046-6. Epub 2016 Mar 24. Ophthalmol Ther. 2016. PMID: 27010720 Free PMC article. Review.
Besifloxacin possesses balanced activity against bacterial topoisomerase II (also called DNA gyrase) and topoisomerase IV. ...Additionally, besifloxacin applied twice daily for 3 days demonstrated greater efficacy than vehicle in treating bacterial conjunctivitis. .
Besifloxacin possesses balanced activity against bacterial topoisomerase II (also called DNA gyrase) and topoisomerase IV. ...Additio
Besifloxacin in the management of bacterial infections of the ocular surface.
Deschênes J, Blondeau J. Deschênes J, et al. Can J Ophthalmol. 2015 Jun;50(3):184-91. doi: 10.1016/j.jcjo.2014.12.013. Can J Ophthalmol. 2015. PMID: 26040217 Review.
This review provides an up-to-date summary of studies on causative pathogens in acute bacterial conjunctivitis; recent geographic trends in bacterial resistance among ocular pathogens, including that of methicillin-resistant Staphylococcus aureus; the efficacy of besifloxacin
This review provides an up-to-date summary of studies on causative pathogens in acute bacterial conjunctivitis; recent geographic trends in …
Besifloxacin: A Critical Review of Its Characteristics, Properties, and Analytical Methods.
Tótoli EG, Salgado HRN. Tótoli EG, et al. Crit Rev Anal Chem. 2018 Mar 4;48(2):132-142. doi: 10.1080/10408347.2018.1429885. Epub 2018 Feb 2. Crit Rev Anal Chem. 2018. PMID: 29345957 Review.
There is a high incidence of bacterial resistance to the antimicrobials most commonly used for the treatment of conjunctivitis. In this context, besifloxacin stands out, since it is a fluoroquinolone developed exclusively for topical ophthalmic use, presenting a low risk o …
There is a high incidence of bacterial resistance to the antimicrobials most commonly used for the treatment of conjunctivitis. In this cont …
Besifloxacin ophthalmic suspension for bacterial conjunctivitis.
Nafziger AN, Bertino JS Jr. Nafziger AN, et al. Drugs Today (Barc). 2009 Aug;45(8):577-88. Drugs Today (Barc). 2009. PMID: 19927224 Review.
Besifloxacin hydrochloride ophthalmic suspension 0.6% (Besivance) is a recently approved fluoroquinolone for the topical treatment of bacterial conjunctivitis. ...The biochemical properties, achievement of target pharmacokinetic/pharmacodynamic goals and the restriction of
Besifloxacin hydrochloride ophthalmic suspension 0.6% (Besivance) is a recently approved fluoroquinolone for the topical treatment of
Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis.
O'Brien TP. O'Brien TP. Adv Ther. 2012 Jun;29(6):473-90. doi: 10.1007/s12325-012-0027-7. Epub 2012 Jun 20. Adv Ther. 2012. PMID: 22729919 Review.
It has a C-8 chlorine substituent and is known as a chloro-fluoroquinolone. Besifloxacin possesses relatively balanced dual-targeting activity against bacterial topoisomerase IV and DNA gyrase (topoisomerse II), two essential enzymes involved in bacterial DNA replication, …
It has a C-8 chlorine substituent and is known as a chloro-fluoroquinolone. Besifloxacin possesses relatively balanced dual-targeting …
Besifloxacin-loaded ocular nanoemulsions: design, formulation and efficacy evaluation.
Kassaee SN, Mahboobian MM. Kassaee SN, et al. Drug Deliv Transl Res. 2022 Jan;12(1):229-239. doi: 10.1007/s13346-021-00902-z. Epub 2021 Feb 11. Drug Deliv Transl Res. 2022. PMID: 33575973
The purpose of this study was to develop and evaluate nanoemulsions (NEs) containing besifloxacin for ocular drug delivery. Pseudo ternary phase diagrams were constructed using Triacetin (oil), Cremophor() RH 40 (surfactant), and Transcutol()P (co-surfactant) to identify N …
The purpose of this study was to develop and evaluate nanoemulsions (NEs) containing besifloxacin for ocular drug delivery. Pseudo te …
Drugs for common eye disorders.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2019 Dec 2;61(1586):187-194. Med Lett Drugs Ther. 2019. PMID: 31770361 Review. No abstract available.
123 results